T2705
拓扑替康 盐酸盐 水合物
≥98% (HPLC and enzymatic), powder, topoisomerase I inhibitor
同義詞:
9-[（二甲基氨基）甲基]-10-羟基-（20S）-喜树碱 盐酸盐 水合物, NSC-609669 盐酸盐 水合物, SKF-104864A 盐酸盐 水合物, 拓扑替康 盐酸盐 水合物
登入查看組織和合約定價
全部照片(1)
About This Item
經驗公式（希爾表示法）:
C23H23N3O5 · xHCl · yH2O
CAS號碼:
分子量：:
421.45 (anhydrous free base basis)
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77
推薦產品
產品名稱
拓扑替康 盐酸盐 水合物, ≥98% (HPLC and enzymatic)
化驗
≥98% (HPLC and enzymatic)
形狀
powder
儲存條件
desiccated
protect from light
顏色
yellow
溶解度
DMSO: ≥20 mg/mL
起源
GlaxoSmithKline
儲存溫度
−20°C
SMILES 字串
[n]21c(cc5c([c]2=O)COC(=O)[C@]5(O)CC)c3nc4c(cc3C1)c(c(cc4)O)CN(C)C
InChI
1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1
InChI 密鑰
UCFGDBYHRUNTLO-QHCPKHFHSA-N
基因資訊
human ... TOP1MT(116447)
應用
拓扑替康作为阳性对照，已被用作低氧条件下人神经胶质瘤细胞中HIF-1α 和VEGF抑制剂的鉴定和分析1。它也被用于 体外 PA317细胞的凋亡检测2。
生化／生理作用
拓扑替康是一种拓扑异构酶I抑制剂和凋亡诱导剂。它是一种有效的抗肿瘤药。
特點和優勢
该化合物由GlaxoSmithKline开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。
準備報告
水合盐酸拓扑替康可溶于DMSO，溶解浓度大于等于20 mg/ml。
This product is soluble in water, however, the concentration has not been determined. Various sources state this chemical can be solubilized in water at greater than 1 mg/mL.
訊號詞
Danger
危險聲明
危險分類
Muta. 1B - Repr. 2
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
客戶也查看了
Ian F King et al.
Nature, 501(7465), 58-62 (2013-09-03)
Topoisomerases are expressed throughout the developing and adult brain and are mutated in some individuals with autism spectrum disorder (ASD). However, how topoisomerases are mechanistically connected to ASD is unknown. Here we find that topotecan, a topoisomerase 1 (TOP1) inhibitor
ChunLei Li et al.
International journal of pharmaceutics, 443(1-2), 17-25 (2013-01-16)
Repeated injection of pegylated liposomes could elicit the disappearance of long-circulating characteristic, referred to as "accelerated blood clearance phenomenon." ABC phenomenon typically occurs when entrapped drugs are not cytotoxic, but recently it was reported that multiple doses of pegylated liposomal
Kaleem Ashraf et al.
Pediatric blood & cancer, 60(10), 1636-1641 (2013-05-08)
Reports of responses and toxicities of salvage therapies for relapsed neuroblastoma are rare and often confounded by effects of additional treatments. Our objective was to describe the outcomes and toxicities for a topotecan and cyclophosphamide (TOPO/CTX) regimen for first relapse
Israel Zighelboim et al.
Gynecologic oncology, 130(1), 64-68 (2013-04-18)
We evaluated the activity and safety of the combination of topotecan, cisplatin and bevacizumab in patients with recurrent or persistent carcinoma of the cervix. Eligible patients had persistent or recurrent cervical cancer not amenable to curative intent treatment. No prior
Jerec W Ricci et al.
Molecular cancer therapeutics, 15(12), 2853-2862 (2016-09-28)
Chemotherapeutic resistance remains a challenge in the treatment of ovarian carcinoma, especially in recurrent disease. Despite the fact that most patients with newly diagnosed tumors attain complete remission following cytoreductive surgery and chemotherapy, ovarian carcinoma has a recurrence rate that
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務